Cargando…
Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA
INTRODUCTION: The administration of biologic disease-modifying antirheumatic drugs, including tumor necrosis factor (TNF)-α inhibitors, is observed to interfere with the disease activity and progression. In this study, we aimed to assess the effectiveness and response predictors of adalimumab (ADA),...
Autores principales: | Milota, Tomas, Hurnakova, Jana, Pavelka, Karel, Kristkova, Zlatuse, Nekvindova, Lucie, Horvath, Rudolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935402/ https://www.ncbi.nlm.nih.gov/pubmed/35321118 http://dx.doi.org/10.1177/1759720X221081649 |
Ejemplares similares
-
The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry
por: Skácelová, Martina, et al.
Publicado: (2022) -
Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry
por: Nekvindová, Lucie, et al.
Publicado: (2021) -
Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
por: Smetanova, Jitka, et al.
Publicado: (2022) -
SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients
por: Smetanova, Jitka, et al.
Publicado: (2022) -
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
por: Smetanova, Jitka, et al.
Publicado: (2022)